Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2025-10-17 Major Shareholding Noti…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It contains detailed information about the ownership of securities by an executive named Jeon Dong Woon, including the number of shares owned, changes in ownership, and related dates. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal disclosure of insider holdings. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels. The document length is 2466 characters, which is consistent with a detailed ownership report rather than a brief announcement or a full financial report. Therefore, the correct classification is MRQ with high confidence.
2025-10-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Certain Securities by Executives and Major Shareholders.' It includes detailed information about the ownership of securities by an executive named Shin Jeong Sup, including dates, number of shares owned, changes in ownership, and related details. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange. This type of filing corresponds to a report of personal share transactions or ownership changes by company directors and executives, which matches the definition of 'Director's Dealing' (DIRS). The document length is 2470 characters, which is consistent with a detailed ownership report rather than a brief announcement or a full financial report. Therefore, the correct classification is DIRS with high confidence.
2025-10-17 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (SARSCoV2 변이주 대응 mRNA백신 mCOV의 제1상 임상시험계획승인 신청(IND))
Regulatory Filings Classification · 95% confidence The document is a disclosure about a clinical trial plan approval application for a SARS-CoV-2 variant mRNA vaccine. It provides detailed information about the clinical trial phase, purpose, and regulatory submission to the Korean Ministry of Food and Drug Safety (MFDS). The document is short (1630 characters) and focuses on a material event related to investment judgment rather than financial results or management changes. It does not contain financial statements, audit information, or governance details. It is an announcement of a significant corporate event relevant to investors, specifically a regulatory or material event disclosure. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-01 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'EuBiologics Co., Ltd.' covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial statements, business descriptions, management analysis, and governance information, which are standard components of an interim/quarterly report. It is not an announcement of a report, but the report itself. H1 2025
2025-08-13 Korean
투자판단관련주요경영사항 (유티프씨주멀티도즈(수출용) 백신의 한국 품목허가 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding the approval of a vaccine product (EuTCV Multi-dose) by the Ministry of Food and Drug Safety (MFDS). It is categorized as a 'Major Management Matter' (투자판단 관련 주요경영사항) under the Korean Exchange (KRX) disclosure system. Since it details a specific corporate event (product approval) rather than a general report announcement, and does not fit into specific categories like M&A or Board changes, it falls under the general regulatory filing category.
2025-07-31 Korean
[기재정정]신규시설투자등(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding a 'New Facility Investment' (신규시설투자등). It specifically details a correction (정정신고) to a previous disclosure concerning investment amounts and funding sources for a vaccine production facility. Since this is a specific corporate disclosure regarding capital expenditure and facility investment, it falls under the 'Regulatory Filings' category as it does not fit into more specific categories like M&A or Share Issues.
2025-06-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.